
MT-II
Melanotan II
Potential Benefits
- Research confirms potent stimulation of melanin production and skin darkening
- May provide some UV protection through increased melanin, though not a substitute for sunscreen
- Studies indicate effects on sexual arousal and erectile function as secondary properties
- May suppress appetite based on preclinical and anecdotal data
Recommended Starting Dose
100-250 mcg subcutaneously (very low initial doses recommended to assess tolerance)
Based on published research protocols. Not a prescription.
Dosing Protocol
Protocols typically start at 100-250 mcg to assess tolerance, gradually increasing to 500 mcg-1 mg. Initial loading phase of daily injections until desired pigmentation is reached, followed by maintenance doses 1-2 times per week. UV exposure is required for the tanning effect to manifest.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Skin darkening effects typically begin within 1-2 weeks with UV exposure. Full tanning effect may take 3-4 weeks of loading doses.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Nausea (very common, especially at initial doses)
- Facial flushing
- Fatigue and drowsiness
- Uncontrolled or spontaneous erections
- Darkening of existing moles (raises dermatological concerns)
- Potential for new nevus formation
- Risk of melanoma promotion is a theoretical concern
- Injection site reactions
- Not manufactured under pharmaceutical standards; quality control concerns
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.